Core Viewpoint - The company Fulejia, known as the "first stock in medical beauty masks," has reported a significant decline in both revenue and net profit for the first half of 2025, marking its worst performance since going public [2][3]. Financial Performance - The company's revenue decreased by 8.15% to 863 million yuan, down from 940 million yuan in the same period of 2024, marking the first negative growth in half-year revenue since its listing [2][3]. - Net profit fell by 32.54% to 230 million yuan, down from 341 million yuan year-on-year, with non-recurring net profit nearly halved, dropping by 48.66% [2][3]. - In Q1 2025, revenue was 301 million yuan, a significant decline of 26.39%, while net profit was 91 million yuan, down 39.77% [3]. - Q2 2025 saw revenue of 562 million yuan, a slight increase of 5.9%, primarily driven by online promotions of cosmetic products, but net profit still declined by 26.72% to 138 million yuan [3][4]. Cost Structure and Profitability - Sales expenses surged to 420 million yuan in the first half of 2025, a year-on-year increase of 39.56%, accounting for 48.67% of total revenue [4][8]. - The gross margin for cosmetic products decreased by 1.11 percentage points to 80.42%, despite a revenue increase of 29.95% to 625 million yuan [7][8]. - Medical device product revenue plummeted by 48.07% to 238 million yuan, significantly impacting overall profitability [5][6]. Market and Regulatory Environment - New regulations from the National Medical Products Administration in 2025 require greater transparency in raw material safety information, increasing compliance costs for medical beauty companies [7]. - The company faces challenges from increased regulatory scrutiny and a competitive market, which has led to a decline in consumer trust due to over-promotional practices [7][11]. Strategic Recommendations - Experts suggest that the company should enhance R&D investment to improve product innovation and diversify its distribution channels, particularly by strengthening partnerships with offline medical beauty institutions [11]. - There is a need for the company to shift its focus from heavy marketing expenditures to building a robust product development strategy to regain market confidence and ensure long-term sustainability [11].

Core Viewpoint - The medical beauty industry is experiencing a significant transformation as pharmaceutical companies and beauty brands aggressively enter the market, indicating a restructuring of industry boundaries driven by consumer upgrades and technological revolutions [1][9]. Group 1: Industry Dynamics - Major pharmaceutical players are rapidly entering the medical beauty sector, with all four major pharmaceutical distribution giants—Sinopharm, Shanghai Pharmaceuticals, China Resources Pharmaceutical, and Jiuzhoutong—now involved in the medical beauty space [3][5]. - Jiuzhoutong was the first to recognize the potential of the medical beauty market, investing in Aimeike in 2016 and subsequently collaborating with other companies, achieving a significant increase in its medical beauty service institutions to 10,560, a year-on-year growth of 84.81% [5][9]. - The medical beauty market in China is projected to reach a scale of 638.2 billion yuan by 2030, with a compound annual growth rate (CAGR) of 14.5% from 2021 to 2030 [9]. Group 2: Investment Trends - Notable investments include Zhong Shanshan, the former richest man in China, who invested 3.4 billion yuan in Jinbo Biotechnology, becoming its second-largest shareholder, highlighting the growing interest in the collagen market [6][9]. - Jiuzhoutong reported a significant increase in its medical beauty revenue, achieving 851 million yuan in sales for 2024, a year-on-year increase of 120.47%, with a three-year CAGR of 111.64% [9]. Group 3: Market Opportunities - The medical beauty sector is attracting beauty brands, with companies like Chuangyan Biotechnology and Proya entering the market with medical-grade products, indicating a shift towards higher-quality offerings [12][13]. - The demand for medical-grade products is rising, with single-use medical dressings priced between 15 to 35 yuan, reflecting consumers' willingness to pay for higher-quality solutions [13]. Group 4: Competitive Strategies - Companies are adopting various strategies to enter the medical beauty market, including investment and acquisition, technology extension, brand crossover, channel integration, and medical-research collaboration [15]. - The future winners in the medical beauty space are expected to be those who can integrate the entire supply chain from research to sales, emphasizing safety and effectiveness in product offerings [15].